CVAC Systems Inc. and Veterans Affairs Palo Alto Health Care System ('VAPAHCS') sign clinical research agreement.

TEMECULA, Calif. -- CVAC Systems Inc. (www.cvacsystems.com) announced today that it has signed a clinical research agreement with Veterans Affairs Palo Alto Health Care System ('VAPAHCS') "to investigate and research the clinical applications of CVAC(TM) (Cyclic Variations in Altitude Conditioning) technology." Principal investigator will be Anne L. Friedlander, Ph.D., Associate Director for Education and Evaluation at VAPAHCS's Geriatric Research Education and Clinical Center, and a consulting professor for the program in Human Biology at Stanford University.

Dr. Friedlander's initial investigations will be intended to provide data on the efficacy of the CVAC process to enhance human performance in young, healthy subjects. In addition, Dr. Friedlander will pursue pilot data and other projects investigating additional potential applications for the CVAC process in varied subject populations. These additional data will be used to calculate the appropriate sample size for further and larger clinical trials. Potential applications of the CVAC process, in addition to enhancing human performance, may include, but are not limited to: recovery from physical exertion; recovery from blood donation; reduction in inflammation and swelling from injury and surgery; improvements in wound healing; and reduction in pain resulting from strain, exertion, trauma, surgery, injury, amputation or aging.

"We have experience with more than 30,000 hours of CVAC applied to individuals of various ages and health conditions for the purpose of improving their physical fitness. Therefore, we are very excited to have Dr. Friedlander and her VAPAHCS team add their scientific observations about CVAC to our clinical experiences," said Allen J. Ruszkowski, President and CEO of CVAC Systems.

The CVAC process uses dynamic changes in air pressure that simulate changes in altitude--triggering the high-altitude adaptation response, which is understood to evoke increases in red blood cell mass and capillary density. Moreover, the ability of the CVAC process to enhance tissue oxygenation and removal of toxins from the body suggests that it could benefit individuals who experience the limit of human performance, whether it is a result of athletic exertion, sickness, or the aging process. "Because the availability of oxygen and removal of toxins are fundamental to life itself, we believe that the number of individuals in the United States who might benefit from the CVAC process is more than 100 million," added Ruszkowski.

Palo Alto, Calif.-based VAPAHCS is one of the largest medical centers in the Department of Veterans Affairs. Approximately 325,000 veterans reside within VAPAHCS's primary service area, of which more than 80,000 are served by VAPAHCS.

CVAC Systems Inc. is headquartered in Temecula, Calif. The Company is privately funded and is currently negotiating a strategic partnership in the physical therapy and rehabilitation sector. The Company seeks to place CVAC instruments at key luminary research sites for the development of performance enhancement and therapeutic health-related applications in several patent-pending applications. For these plans, the Company is seeking a first-round venture/institutional financing.

Please note: The information contained within this document is intended for prospective investors only, and is not intended for patients or health care providers. Any references to therapeutic applications are for discussion and investment purposes only.